Comunicazione EMA su Dienogest etinilestradiolo (27/01/2017)
L’Agenzia Europea dei Medicinali (EMA) ha concluso la revisione della
associazione di dienogest/etinilestradiolo e ha aggiornato le raccomandazioni
sull’impiego.
Italiano
L’Agenzia Europea dei Medicinali (EMA) ha concluso la revisione della
associazione di dienogest/etinilestradiolo e ha aggiornato le raccomandazioni
sull’impiego.
Injected particulate may result in local swelling, irritation of blood vessels or tissue, blockage of blood vessels and/or low-level allergic response to the particulate.
Injected particulate may result in local swelling, irritation of blood vessels or tissue, blockage of blood vessels and/or low-level allergic response to the particulate.
Updated recommendations to help prevent the spread of infection associated with the use of these devices.
Device has shut down unexpectedly during patient treatment, which may expose patients to the risk of serious harm or death. Posted 01/14/2017
Fuji removing legacy 250/450 duodenoscope models from clinical use, replacing with with the ED-530XT model.
Consumers who use a contaminated product are at risk for serious, potentially life-threatening infections.
The particulate matter could enter into the patient and cause serious adverse health consequences including infection, damage of tissue, and death.
Reports of serious adverse events, including patient injury & death, describing medication dosing inaccuracies and other mechanical problems with pumps after an MRI exam.
These vulnerabilities, if exploited, could allow an unauthorized user to remotely access a patient's RF-enabled implanted cardiac device by altering the Merlin@home Transmitter.
80.211.154.110